| Combination of | |
|---|---|
| Vildagliptin | Dipeptidyl peptidase-4 inhibitor |
| Metformin | Biguanide antihyperglycemic agent |
| Clinical data | |
| Trade names | Eucreas, Galvumet, Zomarist, others |
| AHFS/Drugs.com | UK Drug Information |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Vildagliptin/metformin, sold under the brand nameEucreas among others, is afixed-dose combinationanti-diabetic medication for the treatment oftype 2 diabetes.[3] It was approved for use in the European Union in November 2007,[4] and the approval was updated in 2008.[5][6][7] It combines 50 mgvildagliptin with either 500, 850, or 1000 mgmetformin.[8]
The most common side effects include nausea (feeling sick), vomiting, diarrhea, abdominal (tummy) pain and loss of appetite.[4][6][7]
Vildagliptin/metformin is indicated in the treatment of type-2 diabetes mellitus:[4][6][7]
